GO:0097645 amylin binding: Mechanism & Genes

GO:0097645, amylin binding, is a Gene Ontology molecular_function term describing the selective, non-covalent interaction of a protein or macromolecular complex with amylin, a 37-residue peptide hormone co-secreted with insulin from pancreatic beta cells. Amylin (also known as islet amyloid polypeptide, IAPP) circulates in the blood and acts on multiple tissues, and its binding to specific receptors initiates signaling that regulates satiety, gastric emptying, and glucose homeostasis. The term captures the ligand-recognition step that precedes receptor activation, and it is therefore central to understanding how amylin and its therapeutic analogues exert their biological effects. Biochemical characterization of amylin binding sites dates to the early 1990s, when specific, saturable amylin binding was demonstrated in a human hepatoblastoma cell line, providing one of the first experimental definitions of an amylin receptor. Subsequent work established that the principal amylin receptor is a heterodimer formed by the calcitonin receptor (CTR) and a receptor activity-modifying protein (RAMP), with RAMP1 and RAMP3 generating the AMY1 and AMY3 subtypes, respectively. This heterodimeric architecture explains why amylin binding specificity and signaling are determined not only by the ligand but also by the RAMP subunit composition. For researchers, GO:0097645 provides a precise annotation target for experiments that measure ligand-receptor engagement, including radioligand binding, surface plasmon resonance, and structural biology. The term is also relevant to emerging therapeutic modalities: long-acting amylin analogues such as cagrilintide bind brain amylin receptors to reduce body weight, and engineered protein binders and graphitic nanoflakes are being developed to recognize amylin and modulate its structure. Understanding amylin binding at molecular resolution is thus essential for metabolic drug discovery and for probing amylin's role in disease.

In the Gene Ontology, GO:0097645 (amylin binding) is defined as the molecular function of binding to amylin. It describes the selective interaction between a binding partner (typically a receptor or engineered binder) and the amylin peptide, without specifying downstream signaling events. The term is a child of peptide binding and is used to annotate gene products that physically associate with amylin.

Amylin binding is important because it is the molecular gateway through which amylin and its therapeutic analogues initiate signaling that controls appetite, gastric emptying, and glucose homeostasis. The binding event determines receptor subtype selectivity, and structural studies of cagrilintide bound to calcitonin and amylin receptors have revealed how agonist chemistry can be tuned to favor amylin receptor engagement. Because amylin also has renal effects and contributes to islet amyloid pathology, understanding its binding partners is relevant to metabolic, renal, and neurodegenerative disease research. The term also guides the development of engineered binders and nanomaterials that recognize amylin, which are valuable tools for diagnostics and for dissecting amylin biology.

The following genes and proteins are directly implicated in amylin binding, either as receptor subunits, ligands, or engineered binding reagents described in the cited literature.

Amylin binding is regulated primarily by the availability and composition of receptor subunits. The calcitonin receptor (CALCR) must heterodimerize with a RAMP to create a high-affinity amylin binding site, and the identity of the RAMP (RAMP1 versus RAMP3) determines whether the AMY1 or AMY3 subtype is formed. Agonist binding itself modulates subunit interactions, so regulation is bidirectional: receptor composition sets the binding potential, and ligand engagement reshapes the complex. In the brain, regional expression of CTR and RAMPs defines amylin circuitry and determines where amylin analogues act. Peripheral tissues such as liver and kidney also display amylin binding, indicating that regulation extends beyond the central nervous system.

Amylin binding is directly relevant to obesity and metabolic disease because amylin analogues such as cagrilintide lower body weight through brain amylin receptors 1 and 3. Structural studies of cagrilintide bound to calcitonin and amylin receptors support rational design of next-generation anti-obesity drugs. The central amylin circuitry that mediates these effects is a key target for therapeutic intervention.

Amylin has renal effects, and amylin binding in the kidney contributes to its actions on renal function. Understanding peripheral amylin binding sites is therefore relevant to conditions in which amylin clearance or signaling is altered. The hepatoblastoma cell line model provided early evidence for peripheral amylin binding sites outside the brain.

Amylin is the precursor of islet amyloid deposits, and its binding interactions and aggregation propensity are linked to beta-cell dysfunction in diabetes. Nanomaterials such as graphitic nanoflakes can modulate amylin structure and binding, offering experimental tools to study amyloid-related pathology. Engineered binders to disordered proteins may also help interrogate amylin conformers.

Radioligand binding remains a classical method to quantify amylin binding sites, as demonstrated by the characterization of specific amylin binding in human hepatoblastoma cells. These assays measure saturability, affinity, and competition, and can be adapted to cells expressing defined CTR/RAMP combinations.

Structural and dynamic studies of cagrilintide bound to calcitonin and amylin receptors reveal the molecular details of amylin binding and agonist-dependent conformational changes. Such approaches are essential for understanding subtype selectivity and for guiding analogue design.

Diffusing protein binders to intrinsically disordered proteins provide new tools to detect and manipulate amylin, which is itself disordered. These binders can be used in imaging, pull-down, and functional assays to study amylin binding in complex environments.

Graphitic nanoflakes modulate the structure and binding of human amylin, offering a materials-based approach to study amylin recognition and aggregation. Such assays complement biological receptor studies and can reveal non-canonical binding surfaces.

Researchers studying amylin binding-related genes often need to determine whether a candidate gene is causally involved in ligand recognition, receptor assembly, or downstream signaling. EDITGENE provides CRISPR-based cell models and screening services that allow precise interrogation of GO:0097645-associated genes such as CALCR, RAMP1, and RAMP3, as well as engineered binder and overexpression systems for functional validation.

GO:0097645 (amylin binding) defines the selective molecular interaction between amylin and its binding partners, principally CTR/RAMP heterodimers that form the AMY1 and AMY3 receptor subtypes. This binding event is the foundation for amylin physiology and for the therapeutic action of analogues such as cagrilintide. Continued structural, biochemical, and CRISPR-based studies will clarify how receptor composition and agonist chemistry shape amylin recognition in health and disease.